Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B | Q13224 | 1/20 | 0.58 |
| ▸ | WDR5 | P61964 | 1/20 | 0.56 |
| ▸ | BRAF | P15056 | 1/20 | 0.50 |
| ▸ | KDM1A | O60341 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.43 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1009423 | 1.00 | GRIN2B (0.58) | GRIN2BWDR5BRAFKDM1ASMN1; SMN2 | |
| SCHEMBL10092621 | 0.91 | KDM1A (0.54) | GRIN2BWDR5BRAFKDM1AMEN1 | |
| Benzamidoxime SCHEMBL30242 | 0.85 | KMT2A (0.58) | GRIN2BKDM1AMEN1KMT2AMAPT | |
| SCHEMBL22872296 | 0.85 | KMT2A (0.58) | GRIN2BKDM1AMEN1KMT2AMAPT | |
| Benzamidoxime SCHEMBL102483 | 0.85 | KMT2A (0.58) | GRIN2BKDM1AMEN1KMT2AMAPT | |
| Benzamidoxime SCHEMBL872652 | 0.85 | KMT2A (0.58) | GRIN2BKDM1AMEN1KMT2AMAPT | |
| Benzamidoxime SCHEMBL9211538 | 0.83 | KMT2A (0.56) | GRIN2BKDM1AMEN1KMT2AMAPT | |
| Benzamidoxime SCHEMBL27457742 | 0.83 | POLB (0.58) | GRIN2BKDM1AMEN1KMT2AMAPT | |
| SCHEMBL21215222 | 0.83 | KDM1A (0.60) | KDM1AMEN1KMT2AMAPTKDM4E | |
| SCHEMBL21215226 | 0.80 | GFER (0.55) | GRIN2BKDM1ASMN1; SMN2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7951793-B2 | Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-05-31 | — | — | US | disclosed |
| US-7951793-B2 | Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-05-31 | — | — | US | disclosed |
| US-20110118236-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-05-19 | — | — | US | disclosed |
| EP-2269990-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2011-01-05 | — | — | EP | disclosed |
| US-20070293530-A1 | SULFAMIDE AND SULFAMATE DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS | METHYLGENE INC. (CA) | 2007-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118236-A1 | HETEROCYCLIC COMPOUND | GRIN1, GRM1, GRIK1 | GRIN2B 9/4885WDR5 3231/4885BRAF 1100/4885 |
| US-20070293530-A1 | SULFAMIDE AND SULFAMATE DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS | HDAC1, HDAC11, HAT1 | GRIN2B 1016/4885WDR5 1005/4885BRAF 551/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.